PEDPRM

Paediatric Prolonged-Release Melatonin has successfully completed a Phase III clinical trial in neurodevelopmental disabled children suffering from sleep disorders. It met the primary efficacy endpoint demonstrating statistically significant improvement in total sleep time (TST) compared to placebo. In addition to TST, secondary efficacy endpoints demonstrating improvements in sleep initiation and maintenance were also met. Safety profile was similar between PedPRM and placebo-treated groups.
Neurim is moving forward with regulatory submissions for this product.

  • Text size: A A A
  • Circadin
  • Recent news

    • Positive Phase III Results for Neurim Pharmaceuticals’ Pediatric Prolonged-Release Melatonin for Insomnia in Children with Autism Spectrum Disorder (ASD) Presented at the World Sleep Congress in Prague
    • Neurim Pharmaceuticals’ New Paediatric Prolonged-Release Melatonin (“PedPRM”) to Be Marketed by Flynn Pharma in UK and Ireland
    • Positive Results of Pivotal Phase III Study of Pediatric Prolonged-Release Melatonin (PedPRM) for Insomnia in Children with Autism Spectrum Disorder (ASD) to be Presented at the World Sleep Congress in Prague on October 9th
  • Partners

    Partners